Global Head Development News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Global head development. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Global Head Development Today - Breaking & Trending Today

BLOOMBERG Lunch Money April 28, 2014

Are concerned about the global economy. Do you feel like he is not as concerned as everybody elses. Steve is playing in the private markets. Those investments take a lot longer to mature. Whether he feels relaxed or not it is not easy to move illiquid assets if you are a black so if you are a Blackstone Group and one of the things we talked about was russia. Impossible not to talk about russia. Steve sits on an International Advisory panel. That is a position he still holds. I want you to hear Steve Schwarzman talking about the rifts in russia and how he plans to respond. I think in the short term, other than if you are a market operator, which we are not, we buy assets on a longerterm basis as a rule in most of our businesses. It is time to watch. This can have a variety of from going back to business as usu ....

United States , New York , City Of , United Kingdom , San Francisco , Steve Schwarzman , Bbob Iger , David Walker , Beverly Hilton , Alan Mulally , Steve Tannenbaum , Michael Moore , Los Angeles , Kurt Cobain , Whatsapp Facebook , Jeb Bush , Raj Nair , Bruce Springsteen , Brian Cavanagh , Brian Moynihan , Ryan Kavanaugh , Blackstone Group , Group One , International Advisory , Howard Mark , Stock Market ,

Novartis International AG: Novartis reports positive topline results from second Phase III trial of Beovu in patients with diabetic macular edema

Novartis International AG: Novartis reports positive topline results from second Phase III trial of Beovu in patients with diabetic macular edema
,
Beovu (brolucizumab 6 mg) achieved its primary endpoint of non-inferiority to aflibercept 2 mg in change in best-corrected visual acuity (BCVA) at year one (week 52)
1
In a secondary endpoint, more than half of Beovu patients in the 6 mg arm were maintained on a three-month dosing interval through year one, following the loading phase
1
Significant improvement with Beovu 6 mg in change of central subfield thickness (CST) from baseline over the period of week 40 through week 52 was observed
1
1
Novartis intends to submit the data from KESTREL, together with the data from the pivotal Phase III KITE ....

United States , Eric Althoff , Isabella Zinck , Dirk Sauer , Thomas Hungerbuehler , Amy Wolf , Indianj Ophthalmol , Samir Shah , Beovu Basel , Sloan Simpson , Kite Pharma Inc , Novartis Division Communications , Novartis Us External Communications , Novartis External Communications , Exchange Commission , Canadian Drug Expert Committee Recommendation , Global Head Development , National Eye Institute , National Health Insurance Pricing , Canadian Agency For Drugs , Technologies In Health , Association For Research , Novartis Pharma , Kite Pharma , Patients With Visual Impairment Due , Diabetic Macular Edema ,

Novartis reports positive topline results from second Phase III trial of Beovu in patients with diabetic macular edema

Posted December 15th, 2020 for Novartis
In Phase III KESTREL study
,
Beovu (brolucizumab 6 mg) achieved its primary endpoint of non-inferiority to aflibercept 2 mg in change in best-corrected visual acuity (BCVA) at year one (week 52)
1
In a secondary endpoint, more than half of Beovu patients in the 6 mg arm were maintained on a three-month dosing interval through year one, following the loading phase
1
Significant improvement with Beovu 6 mg in change of central subfield thickness (CST) from baseline over the period of week 40 through week 52 was observed
1
1
Novartis intends to submit the data from KESTREL, together with the data from the pivotal Phase III KITE ....

United Kingdom , United States , Eric Althoff , Isabella Zinck , Dirk Sauer , Thomas Hungerbuehler , Amy Wolf , Indianj Ophthalmol , Samir Shah , Beovu Basel , Sloan Simpson , Kite Pharma Inc , Novartis Division Communications , Novartis Us External Communications , Novartis External Communications , Exchange Commission , Canadian Drug Expert Committee Recommendation , Global Head Development , National Eye Institute , National Health Insurance Pricing , Canadian Agency For Drugs , Technologies In Health , Association For Research , Novartis Pharma , Kite Pharma , Patients With Visual Impairment Due ,

Novartis reports positive topline results from second Phase III trial of Beovu® in patients with diabetic macular edema – IT Business Net

In Phase III KESTREL study
,
Beovu (brolucizumab 6 mg) achieved its primary endpoint of non-inferiority to aflibercept 2 mg in change in best-corrected visual acuity (BCVA) at year one (week 52)
1
In a secondary endpoint, more than half of Beovu patients in the 6 mg arm were maintained on a three-month dosing interval through year one, following the loading phase
1
Significant improvement with Beovu 6 mg in change of central subfield thickness (CST) from baseline over the period of week 40 through week 52 was observed
1
1
Novartis intends to submit the data from KESTREL, together with the data from the pivotal Phase III KITE
2
study in DME, to health authorities in H1 2021 ....

United States , Eric Althoff , Isabella Zinck , Dirk Sauer , Thomas Hungerbuehler , Amy Wolf , Indianj Ophthalmol , Samir Shah , Beovu Basel , Sloan Simpson , Kite Pharma Inc , Novartis Division Communications , Novartis Us External Communications , Novartis External Communications , Exchange Commission , Canadian Drug Expert Committee Recommendation , Global Head Development , National Eye Institute , National Health Insurance Pricing , Canadian Agency For Drugs , Technologies In Health , Association For Research , Novartis Pharma , Kite Pharma , Patients With Visual Impairment Due , Diabetic Macular Edema ,